Pub. Date : 2020 Jan
PMID : 31499095
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Among current ACLY inhibitors, Bempedoic acid (ETC-1002) is a first-in-class, prodrug-based direct competitive inhibitor of ACLY which regulates lipid metabolism by upregulating hepatic LDL receptor (LDLr) expression and activity. | 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid | ATP citrate lyase | Homo sapiens |
| 2 | Among current ACLY inhibitors, Bempedoic acid (ETC-1002) is a first-in-class, prodrug-based direct competitive inhibitor of ACLY which regulates lipid metabolism by upregulating hepatic LDL receptor (LDLr) expression and activity. | 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid | ATP citrate lyase | Homo sapiens |
| 3 | Among current ACLY inhibitors, Bempedoic acid (ETC-1002) is a first-in-class, prodrug-based direct competitive inhibitor of ACLY which regulates lipid metabolism by upregulating hepatic LDL receptor (LDLr) expression and activity. | 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid | ATP citrate lyase | Homo sapiens |
| 4 | Among current ACLY inhibitors, Bempedoic acid (ETC-1002) is a first-in-class, prodrug-based direct competitive inhibitor of ACLY which regulates lipid metabolism by upregulating hepatic LDL receptor (LDLr) expression and activity. | 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid | ATP citrate lyase | Homo sapiens |